Transcatheter aortic valve implantation for degenerative aortic valve regurgitation long after heart transplantation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 24182478.
- Also identified by DOI 10.1016/j.athoracsur.2013.03.040.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Transcatheter aortic valve implantation (TAVI) has become a feasible therapeutic option for the management of high-risk patients with severe degenerative aortic stenosis. Recently it has been extended to high-risk patients with severe aortic regurgitation. Degenerative aortic valve disease is generally uncommon in heart transplant recipients. We report the case of a 75-year-old man in whom severe degenerative aortic regurgitation developed 14 years after heart transplantation (HTx). Because of multiple comorbidities and high surgical risk, TAVI was preferred. A 29-mm CoreValve prosthesis (Medtronic Inc, Minneapolis, MN) was successfully implanted using a transfemoral approach.
Medical subject headings
- Aortic Valve
- Aortic Valve Insufficiency
- Heart Transplantation
- Heart Valve Prosthesis Implantation
- Postoperative Complications